Medeia Therapeutics

Medeia Therapeutics is a biotechnology company focused on developing small molecule therapies for neurodegenerative diseases, specifically targeting the toxic protein aggregates that drive conditions like Alzheimer's and Parkinson's. The company's approach involves identifying compounds that can selectively inhibit the formation of these aggregates or promote their clearance, aiming to halt disease progression. Medeia's lead programs are currently in the preclinical stage, leveraging a proprietary discovery platform to address high unmet medical needs in the aging population. Based in San Francisco, the company is supported by venture capital firms such as BlueYard Capital.